SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Secreted protein acidic and rich in cysteine-like 1 (SPARCL1) is implicated in tumor pathogenesis.
• Understanding SPARCL1's role in colorectal cancer (CRC) is crucial for clinical and biological insights.

Purpose of the Study:

• To evaluate the clinical significance of SPARCL1 in colorectal cancer (CRC).
• To explore the potential biological roles of SPARCL1 in CRC development and progression.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets to analyze SPARCL1 expression in CRC.
• Performed ROC curve analysis for diagnostic value and conducted a meta-analysis of clinical studies.
• Employed cBioPortal for coexpression gene identification and R packages (clusterProfiler, ESTIMATE, GSVA) for pathway and tumor microenvironment analysis.

Main Results:

• SPARCL1 was significantly downregulated in CRC tissues, demonstrating high diagnostic accuracy.
• SPARCL1 expression correlated with differentiation, tumor stage, metastasis, and overall survival.
• SPARCL1 and its coexpressed genes are involved in pathways like focal adhesion and PI3K-Akt signaling, and correlate with tumor microenvironment components and immune cells.

Conclusions:

• SPARCL1 is a significant biomarker in colorectal cancer.
• SPARCL1's expression is closely linked to clinicopathological features and the tumor microenvironment in CRC.